IPO cash to put Kythera's chin thinner through Phase III
This article was originally published in Scrip
Executive Summary
Kythera Biopharmaceuticals has established a price range of $14 to $16 per share for an initial public offering of four million shares, which would give the company gross proceeds of $60 million at the mid-point to fund Phase III clinical trials for its chin-thinning drug ATX-101.